Nature Biotechnology
16, 444 - 448 (1998)
doi:10.1038/nbt0598-444
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyMaureen Chase1, Richard Y. Chung1
& E. Antonio Chiocca1, *
1Molecular Neuro-oncology Laboratories, Neurosurgical Service, Massachusetts General Hospital-CNY6, Harvard Medical School, Charlestown, MA 02129.
*e-mail: Chiocca@helix.MGH.Harvard.edu. Herpes simplex viruses type 1 (HSV-1) with an inactivated viral ribonucleotide reductase (Hsrr, ICP6) were designed to target tumor cells with upregulated mammalian ribonucleotide reductase (mRR), an enzyme whose expression is regulated by the p16/pRB tumor suppressor pathway. A recombinant HSV-1 was generated by knock-out of Hsrr and insertion of the rat CYP2B1 transgene responsible for the bioactivation of the prodrugs, cyclophosphamide and ifosfamide. The mutant virus replicated selectively in rat and human tumor cells that express mRR. Addition of cyclophosphamide potentiated oncolytic effects against cultured tumor cells and subcutaneous tumor xenografts established in athymic mice.
REFERENCES
- Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. and Coen, D.M. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854−856. | PubMed | ISI | ChemPort |
- Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D. and Martuza, R.L. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1: 938−943. | Article | PubMed | ISI | ChemPort |
- Boviatsis, E.J., Park, J.S., Sena-Esteves, M., Kramm, C., Chase, M., Efird, J. et al. 1994. Long-term survival of rats harboring brain tumors treated with ganci-clovir and a herpes simplex virus vector that maintains an intact thymidine kinase gene. Cancer Res. 54: 5745−5751. | PubMed | ISI | ChemPort |
- Chambers, R., Gillespie, G.Y., Soroceanu, L., Andreasky, S., Chatterjee, J., Chou, J. et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92: 1411−1415 1995. | PubMed | ChemPort |
- Pyles, R.B., Wamfck, R.E., Chalk, C.L., Szanti, B.E. and Parysek, L.M. A novel multiply-mutated HSV-1 strain for the treatment of brain tumors. Hum. Gen. Ther. 8: 533−544 1997. | ISI | ChemPort |
- Goldstein, D.J. and Weller, S.K. Herpes simplex virus type 1-induced ribonu-cleotlde reductase activity is dispensable for virus growth and DNA synthesis:isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62: 196−205 1988. | PubMed | ISI | ChemPort |
- Kesari, S., Lee, V.M.Y., Brown, S.M., Trojanowski, J.Q. and Fraser, N.W. 1995. Therapy of experimental brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73: 636−648. | PubMed | ISI | ChemPort |
- Lorence, R.M., Reichard, K.W., Katubig, B.B., Reyes, H.M., Phuangsab, A., Mitchell, B.R. et al. 1994. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86: 1228−1233. | PubMed | ChemPort |
- Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M. et al. 1996. An adenovirus mutant that replicates selectively in p53-deflcient human tumor cells. Science 274: 373−376. | Article | PubMed | ISI | ChemPort |
- Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W. and Henderson, D.R. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559−2563. | PubMed | ISI | ChemPort |
- Wei, M.X., Tamiya, T., Chase, M., Boviatsis, E.J., Chang, T.K.H., Hochberg, F.H. et al. 1994. Experimental tumor therapy in mice with the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5: 969−978. | PubMed | ISI | ChemPort |
- Chen, L. and Waxman, D.J. 1995. Intratumoral activation and enhanced chemotherapeu-tic effect of oxazaphosphorines following cytochrome P450 gene transfer development of a combined chemotherapy/cancer gene therapy strategy. Cancer. Res. 55: 581−589. | PubMed | ISI | ChemPort |
- Moolten, F.L. 1994. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1: 279−287. | PubMed | ISI | ChemPort |
- Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., Black, K.L. et al. 1996. 1996Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA 93: 2909−2914. | Article | PubMed | ChemPort |
- Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Person, D.Z. et al. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2: 985−991. | Article | PubMed | ISI | ChemPort |
- Moolten, F.L. 1986. Tumor chemosensitivity conferred by inserted thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46: 5276−5281. | ChemPort |
- Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. and Woo, S.L.C. 1994. Gene therapy for brain tumors: regression of experimental gliomas by using adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91: 3054−3057. | PubMed | ChemPort |
- Mroz, P.J. and Moolten, F.L. 1993. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum. Gene Ther. 4: 589−595. | PubMed | ISI | ChemPort |
- Mullen, C.A., Kilstrup, M. and Blaese, R.M. 1992. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluoro-cytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 59: 33−37.
- Wei, M.X., Tamiya, T., Rhee, R.J., Breakefield, X.O. and Chiocca, E.A. 1995. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with cyctophos-phamide/ cytochrome P450 2B1 gene therapy. Clinical Cancer Research 1: 1171−1177. | PubMed | ISI | ChemPort |
- Marais, R., Spooner, R.A., Light, Y., Martin, J. and Springer, C.J. 1996. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56: 4735−4742. | PubMed | ISI | ChemPort |
- Chen, L., Waxman, D.J., Chen, D. and Kufe, D.W. 1996. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56: 1331−1340. | PubMed | ISI | ChemPort |
- Chen, L. and Waxman, D.J. 1989. Oxidative metabolism of cyclophosphamide: identjfica-tion of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49: 2344−2350. | PubMed | ISI | ChemPort |
- Sidranski, D., Mikkelsen, T., Schwechleimer, K., Rosenblum, M.L., Cavenee, W.K. and Vogelstein, B. 1992. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846−847. | Article | PubMed | ISI | ChemPort |
- Signer, D.D., Signer, S.H., Ponten, J., Westermark, B., Mahaley, M.S., Ruoslahti, E. et al. 1981. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40: 201−229. | PubMed |
- Nilaver, G., Muldoon, L.L., Kroll, R.A., Pagel, M.A., Breakefield, X.O., Davidson, B.L. et al. 1995. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc. Natl Acad. Sci. USA 21: 9829−9833.
- Muldoon, L.L., Nilaver, G., Kroll, R.A., Pagel, M.A., Breakefield, X.O., Chiocca, E.A. et al. 1995. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147: 1840−1851. | PubMed | ISI | ChemPort |
- Ram, Z., Culver, K.W., Oshiro, E., Viola, J.J., De Vroom, H.L., Otto, E. et al. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producer cells. Nat. Med. 3: 1354−1361. | Article | PubMed | ISI | ChemPort |
- McCarthy, A., McMahan, L. and Schaffer, P.A. 1989. Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J. Virol. 63: 18−27. | PubMed | ISI | ChemPort |
- Mineta, T., Rabkin, S.D. and Martuza, R.L. 1994. Treatment of malignant glioma using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex virus mutant. Cancer Res. 54: 3936−3966.
- Lukas, J., Petersen, B.O., Holm, K., Bartek, J. and Helin, K. 1996. Deregulated expression of E2F family members induses S-phase entry and overcomes p76—mediated growth suppression. Mol. Cell. Biol. 16: 1047−1057. | PubMed | ISI | ChemPort |
- Dynlacht, B.D., Flores, O., Less, J.A. and Harlow, E. 1994. Differential regulation of E2F trans-activation by cyclin/cdk2 complexes. Genes. Dev. 8: 1772−1786. | PubMed | ISI | ChemPort |
- DeGregori, J., Kowalik, T. and Nevins, J.R. 1995. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15: 4215−4224. | PubMed | ISI | ChemPort |
- Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A. and Louis, D.N. 1996. CKN2/P16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56: 150−153. | PubMed | ISI | ChemPort |
- Van Meir, E.G., Kikuchi, T., Tada, M., Li, H., Diserens, A.C., Wojcik, B.E. et al. 1994. Analysis of the p53 gene and its expression in human glbblastoma cells. Cancer Res. 54: 649−652. | PubMed | ChemPort |
- Carroll, N.M., Chiocca, E.A. and Tanabe, K.K. 1997. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res. 69: 413−417. | Article | PubMed | ISI | ChemPort |
- Colvin, O.M. 1993. Alkylating agents and platinum compounds pp. 733−734 in Cancer medicine. Holland, J.F, Frei, E., Bast, R.C. Jr., Kufe, D.W., Morton, D.L., and Weichselbaum, R.R. (eds.). Lea and Fabiger, Philadelphia.
- Gopferich, A., Alonso, M.J. and Langer, R. 1994. Development and characterization of microencapulated microspheres. Pharm. Res. 11: 1568−1574. | Article | PubMed | ISI | ChemPort |
|
